Page last updated: 2024-08-21

formestane and Disease Exacerbation

formestane has been researched along with Disease Exacerbation in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jiang, Z; Liu, X; Song, S; Wang, T; Wu, S; Yu, J	1
Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I	1
Coombes, RC; Harper-Wynne, C	1
Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM	1

Trials

3 trial(s) available for formestane and Disease Exacerbation

Article	Year
[Clinical trial of lentaron for postmenopausal patients with advanced breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2002, Volume: 24, Issue:5 Topics: Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Treatment Outcome	2002
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast cancer research and treatment, 2003, Volume: 79, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles	2003
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:5 Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Receptors, Estrogen; Treatment Outcome; Triazoles	1999

Other Studies

1 other study(ies) available for formestane and Disease Exacerbation

Article	Year
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles	2001

Article

Year

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles

2001